Company expects to begin Phase 2 trial of rexaceract in Parkinson's disease in Q3 2026
Final results from Phase 1b clinical study of rexaceract expected in Q4 2026
GT-04686 initial target indication expected to be selected by year end
Overview
Biotechnology firm's Q2 net loss per share narrowed yr/yr to $0.11
R&D expenses fell due to lower costs for lead compound and personnel
FDA cleared IND for rexaceract, enabling Phase 2 clinical development
Result Drivers
R&D EXPENSES - Decrease in R&D expenses was mainly due to lower costs for lead program rexaceract and reduced research and development personnel expenses, partially offset by grant expiration and unfavorable currency translation
G&A EXPENSES - Increase in general and administrative expenses was due to higher professional fees, personnel costs, and unfavorable currency translation
Analyst Coverage
The current average analyst rating on the shares is and the breakdown of recommendations is 5 or , no and no or
GANX•
